Consideration of antibody drug conjugates development and regulation / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1971-1977, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-825175
ABSTRACT
Antibody drug conjugates (ADCs), as they combine the targetability of monoclonal antibody and cytotoxicity of small molecules, are a growing class of therapeutics for cancer. The key factor of ADCs development is the accurate selection of parameters including tumor target, monoclonal antibody, cytotoxic payload, and linkage strategy of antibody to payload. Here, we summarize the main elements in the structural design and the development of ADCs, as well as the regulatory consideration of product manufacturing and control, which would be helpful for the research and development of ADCs.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Acta Pharmaceutica Sinica
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS